A novel mutation of myelin protein zero associated with late-onset predominantly axonal Charcot-Marie-Tooth disease

Deutsche Zeitschrift für Nervenheilkunde - Tập 259 - Trang 1585-1589 - 2012
Maria Marttila1,2, Bernd Rautenstrauss3, Kathrin Huehne4, Virpi Laitinen5,6, Kari Majamaa1,2, Mikko Kärppä1,2
1Department of Clinical Medicine, Neurology, University of Oulu, Oulu, Finland
2Clinical Research Center, Oulu University Hospital, Oulu, Finland
3Medizinisch Genetisches Zentrum and Friedrich-Baur-Institute, University of Munich, Munich, Germany
4Institute of Human Genetics, University Hospital Erlangen-Nuremberg, Erlangen, Germany
5Department of Medical Biochemistry and Genetics, Diagnostic DNA Laboratory, Institute of Biomedicine, University of Turku, Turku, Finland
6Laboratory of Cancer Genetics, Institute of Biomedical Technology (IBT), University of Tampere, Tampere, Finland

Tóm tắt

We report a case of late-onset predominantly axonal Charcot-Marie-Tooth disease resulting from a novel mutation in the MPZ gene encoding myelin protein zero (P0). Neurological examination, electrophysiological examination and genetic testing were performed on three members of a Finnish family (family A) and one member of a German family (family B). Three other members of the Finnish family were interviewed and genetically tested. Genetic testing was also performed on 95 healthy Finnish controls. Three members in two generations of family A and the member of family B were affected with late-onset axonal more than demyelinating, motor and sensory polyneuropathy. Heterozygous c.316C>T mutation in MPZ leading to p.Arg106Cys in P0 was found in all the affected subjects, but not in the three unaffected members of the Finnish family. None of 95 healthy Finnish controls harbored the mutation. The findings of this study indicate that p.Arg106Cys allele in MPZ causes late-onset predominantly axonal sensory and motor neuropathy.

Tài liệu tham khảo

Pareyson D, Marchesi C (2009) Diagnosis, natural history, and management of Charcot-Marie-Tooth disease. Lancet Neurol 8:654–667 Shy ME, Lupski JR, Chance PF et al (2005) Hereditary motor and sensory neuropathies: an overview of clinical, genetic, electrophysiologic, and pathologic features. In: Dyck PJ, Thomas PK (eds) Peripheral neuropathy. Elsevier Saunders, Philadelphia, pp 1623–1658 Bienfait HM, Baas F, Koelman JH et al (2007) Phenotype of Charcot-Marie-Tooth disease Type 2. Neurology 68:1658–1667 Banchs I, Casasnovas C, Alberti A et al (2009) Diagnosis of Charcot-Marie-Tooth disease. J Biomed Biotechnol 2009:985415 Reilly MM, Shy ME (2009) Diagnosis and new treatments in genetic neuropathies. J Neurol Neurosurg Psychiatr 80:1304–1314 Lawson VH, Graham BV, Flanigan KM (2005) Clinical and electrophysiologic features of CMT2A with mutations in the mitofusin 2 gene. Neurology 65:197–204 Verhoeven K, De Jonghe P, Coen K et al (2003) Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy. Am J Hum Genet 72:722–727 Szabo A, Zuchner S, Siska E et al (2005) Marked phenotypic variation in a family with a new myelin protein zero mutation. Neuromuscul Disord 15:760–763 Hayasaka K, Nanao K, Tahara M et al (1991) Isolation and sequence determination of cDNA encoding the major structural protein of human peripheral myelin. Biochem Biophys Res Commun 180:515–518 Shy ME, Jani A, Krajewski K et al (2004) Phenotypic clustering in MPZ mutations. Brain 127:371–384 Shy ME (2006) Peripheral neuropathies caused by mutations in the myelin protein zero. J Neurol Sci 242:55–66 Shy ME, Blake J, Krajewski K et al (2005) Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 64:1209–1214 Rozen S, Skaletsky H (2000) Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132:365–386 Bell J (2008) A simple way to treat PCR products prior to sequencing using ExoSAP-IT. Biotechniques 44:834 Körkkö J, Annunen S, Pihlajamaa T et al (1998) Conformation sensitive gel electrophoresis for simple and accurate detection of mutations: comparison with denaturing gradient gel electrophoresis and nucleotide sequencing. Proc Natl Acad Sci USA 95:1681–1685 De Jonghe P, Timmerman V, Ceuterick C et al (1999) The Thr124Met mutation in the peripheral myelin protein zero (MPZ) gene is associated with a clinically distinct Charcot-Marie-Tooth phenotype. Brain 122:281–290 Ceroni A, Passerini A, Vullo A et al (2006) DISULFIND: a disulfide bonding state and cysteine connectivity prediction server. Nucleic Acids Res 34(Suppl 2):W177–W181 Rouger H, LeGuern E, Gouider R et al (1996) High frequency of mutations in codon 98 of the peripheral myelin protein P0 gene in 20 French CMT1 patients. Am J Hum Genet 58:638–641 Souayah N, Tick Chong PS (2010) Asymmetric phenotype associated with rare myelin protein zero mutation. J Clin Neuromuscul Dis 11:110–113 Boerkoel CF, Takashima H, Garcia CA et al (2002) Charcot-Marie-Tooth disease and related neuropathies: mutation distribution and genotype-phenotype correlation. Ann Neurol 51:190–201 Lee YC, Yu CT, Lin KP et al (2008) MPZ mutation G123S characterization: evidence for a complex pathogenesis in CMT disease. Neurology 70:273–277